Scott Wagner - 21 Jan 2026 Form 4 Insider Report for GoodRx Holdings, Inc. (GDRX)

Reporting relationship: Director
Issuer ticker: GDRX
Reported as of: 21 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 17:20:35 UTC
Prior SEC filing: 03 Nov 2025
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Gracye Cheng, Attorney-in-Fact for Scott Wagner

Key filing fact

Scott Wagner filed Form 4 for GoodRx Holdings, Inc. (GDRX) on 21 Jan 2026.

Key facts

This page summarizes Scott Wagner's Form 4 filing for GoodRx Holdings, Inc. (GDRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2026, 17:20.

Change

Previous filing in this sequence was filed on 03 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001342655 Primary reporting owner

Wagner Scott

Relationship: Director
Address: C/O GOODRX HOLDINGS, INC., 2701 OLYMPIC BOULEVARD, SANTA MONICA
Signature: /s/ Gracye Cheng, Attorney-in-Fact for Scott Wagner
Signature date: 21 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GDRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +31,394
Change %: +17%
Price
Shares after: 216,663
Date: 21 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GDRX transaction Derivative

Deferred Stock Unit

Options Exercise

Transaction value: $0
Shares: -31,394
Change %: -33%
Price: $0.000000
Shares after: 62,788
Date: 21 Jan 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 31,394
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The deferred stock unit award vested as to one-third of the shares underlying the award on January 21, 2026. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2030; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Class A common stock.